Protecting Your Vision as You Age

Almost every piece of eye health advice you will find is written for the moment after something goes wrong. Your doctor spots a change. You get a diagnosis. You start looking for what fixes it.

That is a reasonable way to handle a problem. It is a poor way to handle a system. And your eyes are a system, one that has been running continuously since the day you were born, at a metabolic cost higher than almost any other tissue you own.

So here is a different question, and it is the one worth asking in your fifties rather than your seventies. Not what repairs vision, but what maintains it. Protecting your vision as you age is a maintenance decision. This post covers what that actually means at the cellular level, what the research supports, and, just as importantly, where the evidence runs out.

Why Are Your Eyes So Energy Hungry?

Start with the part most people never hear. The visual system is one of the most energetically demanding systems in the entire body. Your retina is not a passive sheet of film at the back of your eye. It is active nervous tissue, and it is expensive to run.

The reason is a process called phototransduction. Every time light hits a photoreceptor cell, that cell has to fire, then reset itself to be ready for the next photon. The firing is not the costly part. The resetting is. In a 2010 review of visual system energy metabolism, that repolarization work was identified as consuming the bulk of the retina's energy budget (1).

Your eyes do this millions of times a second, in every waking hour, for decades. Think of the retina less like a camera sensor and more like an engine that has never once been switched off.

All of that energy comes from mitochondria, the small power generators inside your cells. Which means the health of your retina is tied directly to the health of its energy supply.

What Happens to That Energy System With Age?

This is where a molecule called NAD+ enters the picture. NAD+ is a coenzyme your mitochondria use to turn fuel into usable energy. Without enough of it, cells struggle to produce the energy they need to do their jobs.

NAD+ levels decline with age. That is well established across tissues, and researchers studying the eye specifically have documented it in the retina.

Put those two facts side by side and the picture gets clear. You have a tissue with an unusually high energy demand, supplied by a system whose capacity quietly decreases over the decades. Nothing dramatic happens on any given day. That is precisely why it goes unnoticed.

This is the same logic behind taking calcium for your bones. You do not feel it working. The absence is what shows up over time.

What Does the Research Actually Show?

Here is where precision matters, because this is a field where the headlines have gotten well ahead of the evidence. Three findings are worth knowing, in order.

The animal research that started the conversation

In 2017, a team publishing in Science studied glaucoma-prone mice and found that mitochondrial abnormalities showed up early, before any detectable degeneration. They also found that retinal NAD+ levels dropped with age, which appeared to leave aging neurons more vulnerable. When the mice were given oral nicotinamide, a form of vitamin B3, the protective effect was substantial. At the highest dose tested, 93 percent of eyes did not develop glaucoma (2).

That is a striking result. It is also a result in mice. Animal findings tell you a mechanism is plausible and worth testing in people. They do not tell you it works in people.

The first human trial

In 2022, researchers at Columbia published a phase 2 randomized clinical trial in JAMA Ophthalmology. Forty two patients with open-angle glaucoma and moderate visual field loss were enrolled, and 32 completed the study. Participants received escalating doses of nicotinamide, up to 3,000 mg, along with pyruvate, over roughly three weeks of dose escalation. The treatment group showed improvement in more visual field test locations than the placebo group (3).

Read that carefully, because the details are the story. Thirty two people who finished. A median follow-up of about two months. A visual field measure, not a long-term outcome. This is an early, small, short trial that justifies larger ones, and larger ones are now underway. It is not a settled question.

What the professional societies said about it

This is the part that matters most for how you should think about all of it. In early 2025, the American Glaucoma Society and the American Academy of Ophthalmology issued a joint position statement on nicotinamide for glaucoma neuroprotection (4).

Two organizations of this standing do not publish a position statement on a supplement unless the science has reached a level worth addressing formally. That is meaningful. Their guidance was also measured, covering dosing questions, liver function monitoring, and the limits of the current evidence. Both halves of that are the honest read: the biology is being taken seriously, and the case is not closed.

Where Does Lutein Fit Into a Maintenance Approach?

Cellular energy is one layer. Lutein is a different one, and it is the layer most people already know something about.

Lutein is a pigment that accumulates in the macula, the small central region of the retina that handles detailed vision. Think of it as internal sunglasses, a filter your body builds and maintains out of what you eat.

The good news is that this one is measurable. In a randomized, double-blind, placebo-controlled trial published in Nutrients in 2020, 59 healthy adults took either 12 mg of lutein daily or a placebo for 16 weeks. The lutein group showed significantly higher macular pigment optical density at week 16 (5).

Note who was studied there. Healthy adults, not patients. That is exactly the maintenance question this post is about, and it is one of the better-characterized answers in the category.

That trial also went a step further than pigment density. It measured contrast sensitivity and glare sensitivity, both of which improved significantly in the lutein group at week 16, though not at the 8 week mark.

The same caveats still apply. This was one trial of 59 adults over 16 weeks, using a high-bioavailability form of lutein at 12 mg, which is somewhat higher than the 10 mg found in Sight Guard. Sixteen weeks also tells you nothing about what happens over twenty years, which is the timeframe that actually matters for a maintenance decision. Real findings, honestly bounded.

Here Is Where You Pump the Brakes

If you are the kind of person who reads the supplement facts panel before buying, you deserve the caveats stated as plainly as the findings.

The doses in those trials were high. The Columbia trial escalated nicotinamide to 3,000 mg, which is far above what any daily eye supplement contains. Nobody should read a trial like that and assume a daily capsule reproduces it.

The molecules are also not interchangeable. The glaucoma trials used nicotinamide. Nicotinamide riboside, which is what appears in most NAD-focused supplements including Sight Guard, is a different compound that also serves as a NAD+ precursor. Both feed the same pathway. They are not the same molecule, and the human trials above were not run on nicotinamide riboside.

And the glaucoma research is research on people who already have glaucoma. It is not evidence about what a supplement does for someone without a diagnosis. Anyone who tells you otherwise is selling past the data.

What all of this supports is narrower and more honest: the cellular energy system in the eye is real, it is measurable, it declines with age, and it is a reasonable thing to support. That is a structure and function statement, not an outcome promise.

What Does This Mean for You?

If you are in your fifties and nothing is wrong, you are in the best possible position, because maintenance is only available before it becomes repair.

A few practical points to take with you.

Keep your eye exams on schedule. Nothing in this post substitutes for someone actually looking at your retina. Screening catches what you cannot feel, and most early changes are silent by design.

Eat for the pigment. Dark leafy greens, egg yolks, and orange and yellow vegetables are where dietary lutein comes from. Okay, reality check: most of us are not eating kale every day, which is part of why the supplement question comes up at all.

Bring it to your doctor rather than around them. If you are considering anything in this category, especially at higher doses, that is a conversation for your next appointment. The AGS and AAO statement specifically raises monitoring considerations, which is exactly the sort of thing your physician should be weighing, not you alone.

Some people add a targeted eye supplement to that routine. Sight Guard was formulated by ophthalmologists around the science of NAD+ and cellular energy in the eye, and it is designed to support optic nerve health as a complement to the care you already have, not a replacement for it.

The Bigger Picture

For most of the last two decades, eye supplementation meant one idea: carotenoids for the macula. That idea was a good one, and lutein still earns its place.

What has changed is that researchers started asking about the energy supply underneath it. The eye is not just a filter that wears down. It is an engine that has to be fed. That question is now serious enough that two major professional societies have written about it formally.

You do not have to wait for the field to finish settling to act sensibly in the meantime. Protecting what you have is not a dramatic decision. It is a boring, repeated, daily one. That is what makes it work.

References

1. Wong-Riley MT. Energy metabolism of the visual system. Eye and Brain. 2010;2:99-116. doi:10.2147/EB.S9078. PMID: 23226947.

2. Williams PA, Harder JM, Foxworth NE, Cochran KE, Philip VM, Porciatti V, Smithies O, John SWM. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756-760. doi:10.1126/science.aal0092. PMID: 28209901.

3. De Moraes CG, John SWM, Williams PA, Blumberg DM, Cioffi GA, Liebmann JM. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmology. 2022;140(1):11-18. doi:10.1001/jamaophthalmol.2021.4576. PMID: 34792559.

4. Shukla AG, Cioffi GA, John SWM, Wang Q, Liebmann JM; American Glaucoma Society and American Academy of Ophthalmology. American Glaucoma Society and American Academy of Ophthalmology position statement on nicotinamide use for glaucoma neuroprotection. Ophthalmology Glaucoma. 2025;8(2):112-116. doi:10.1016/j.ogla.2025.01.002. PMID: 39800263.

5. Machida N, Kosehira M, Kitaichi N. Clinical effects of dietary supplementation of lutein with high bio-accessibility on macular pigment optical density and contrast sensitivity: a randomized double-blind placebo-controlled parallel-group comparison trial. Nutrients. 2020;12(10):2966. doi:10.3390/nu12102966. PMID: 32998324.